Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma

Overview

Journal Breast Care (Basel)

Publisher Karger

Date 2022 Mar 31

PMID 35355703

Authors

Jian Zheng

Yuntao Wei

Xiaoxi Li

Zhan Shen

Yong Zhang

Bo Huang

Youhong Jiang

Daqing Wang

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to measure the expression of PD-L1, CD1a (a marker for immature dendritic cells), and CD83 (a marker for mature dendritic cells) and further examine the associations of PD-L1, CD83, and CD1a with overall survival (OS) in triple-negative breast carcinoma patients.

Methods: PD-L1, CD1a, and CD83 expression in breast carcinoma tissues and CD83 expression in lymph node tissues were examined by immunohistochemistry and tissue microarray in 159 patients. Patients were classified into the low, medium, and high PD-L1, CD1a, and CD83 levels. Pearson χ test was used to analyze the correlations between PD-L1, CD1a, and CD83. The Kaplan-Meier method was used to calculate the OS. Multivariate analysis was used to identify determinants of 3- and 5-year OS.

Results: 25.1, 25.8, and 49.1% of the patients had low, medium, and high PD-L1 levels, respectively. PD-L1 levels significantly correlated with CD1a ( = 0.30409, < 0.001) and CD83 levels ( = 0.6146, < 0.001) in breast carcinoma tissue, as well as CD83 levels ( = 0.17508, = 0.027) in lymph node. The median OS was 83 months (range 12-106), and the 3- and 5-year OS rates were 94.97% (95% CI 91.57-98.37) and 86.79% (95% CI 81.53-92.06), respectively. Moreover, patients with high median CD1a levels had a significantly lower 5-year OS rate (75.6%) than those with low median CD1a levels (93.5%, = 0.038).

Conclusion: PD-L1, CD1a, and CD83 are variably expressed in triple-negative breast carcinoma tissues, and PD-L1 expression correlates with CD1a and CD83. Higher CD1a levels correlate with PD-L1 expression and predict worse OS in triple-negative breast carcinoma.

Citing Articles

The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review.

Andour L, Hagenaars S, Gregus B, Tokes A, Karancsi Z, Tollenaar R Virchows Arch. 2025; .

PMID: 39904885 DOI: 10.1007/s00428-025-04039-z.

Analysis of CD1a-Positive Monocyte-Derived Cells in the Regional Lymph Nodes of Patients with Gallbladder Cancer.

Maeda S, Kai K, Kawasaki K, Tanaka T, Ide T, Noshiro H Int J Mol Sci. 2024; 25(23).

PMID: 39684473 PMC: 11641552. DOI: 10.3390/ijms252312763.

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.

Arqueros C, Gallardo A, Vidal S, Osuna-Gomez R, Tibau A, Lidia Bell O Int J Mol Sci. 2024; 25(5).

PMID: 38473874 PMC: 10932208. DOI: 10.3390/ijms25052627.

References

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

Carey L, Winer E, Viale G, Cameron D, Gianni L . Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010; 7(12):683-92. DOI: 10.1038/nrclinonc.2010.154. View

Detre S, Saclani Jotti G, Dowsett M . A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995; 48(9):876-8. PMC: 502883. DOI: 10.1136/jcp.48.9.876. View

Li X, Wetherilt C, Krishnamurti U, Yang J, Ma Y, Styblo T . Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. Am J Clin Pathol. 2016; 146(4):496-502. DOI: 10.1093/ajcp/aqw134. View

Mittendorf E, Philips A, Meric-Bernstam F, Qiao N, Wu Y, Harrington S . PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2(4):361-70. PMC: 4000553. DOI: 10.1158/2326-6066.CIR-13-0127. View

Mori H, Kubo M, Yamaguchi R, Nishimura R, Osako T, Arima N . The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget. 2017; 8(9):15584-15592. PMC: 5362507. DOI: 10.18632/oncotarget.14698. View

Stovgaard E, Nielsen D, Hogdall E, Balslev E . Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. Acta Oncol. 2017; 57(1):74-82. DOI: 10.1080/0284186X.2017.1400180. View

Aaltomaa S, Lipponen P, Eskelinen M, Kosma V, Marin S, Alhava E . Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992; 28A(4-5):859-64. DOI: 10.1016/0959-8049(92)90134-n. View

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

10.

Fujimoto Y, Tedder T . CD83: a regulatory molecule of the immune system with great potential for therapeutic application. J Med Dent Sci. 2006; 53(2):85-91. View

11.

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M . Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008; 100(2):121-33. DOI: 10.1093/jnci/djm287. View

12.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

13.

Wang C, Zhu H, Zhou Y, Mao F, Lin Y, Pan B . Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. Breast J. 2017; 23(4):436-443. DOI: 10.1111/tbj.12753. View

14.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F . Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31(7):860-7. DOI: 10.1200/JCO.2011.41.0902. View

15.

Wein L, Savas P, Luen S, Virassamy B, Salgado R, Loi S . Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol. 2017; 7:156. PMC: 5540942. DOI: 10.3389/fonc.2017.00156. View

16.

Catacchio I, Silvestris N, Scarpi E, Schirosi L, Scattone A, Mangia A . Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Transl Oncol. 2019; 12(3):585-595. PMC: 6350084. DOI: 10.1016/j.tranon.2018.12.005. View

17.

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N . Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009; 20(12):1913-27. DOI: 10.1093/annonc/mdp492. View

18.

Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T . Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer. 2003; 104(1):92-7. DOI: 10.1002/ijc.10915. View

19.

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

20.

Fedchenko N, Reifenrath J . Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014; 9:221. PMC: 4260254. DOI: 10.1186/s13000-014-0221-9. View